John H. Stone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John H. Stone has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Gary S. Hoffman
Cleveland Clinic Foundation, Cleveland, Ohio
3 shared publicationsJohn C. Davis
University of California, San Francisco
3 shared publicationsPeter A. Merkel
Boston University, Boston, Massachusetts
3 shared publicationsUlrich Specks
Mayo Clinic, Rochester, Minnesota
3 shared publicationsE. William St.Clair
Duke University, Durham, North Carolina
2 shared publicationsEdward H. Yelin
University of California, San Francisco
2 shared publications
Latest Publications
- 27 April 2006
- Published by Wiley in Arthritis & Rheumatism
- Vol. 54 (5) , 1608-1618
Solid malignancies among patients in the Wegener's granulomatosis etanercept trial
Objective: Etanercept is a soluble fusion protein designed to inhibit tumor necrosis factor (TNF). During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo‐controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more solid malignancies were observed in the etanercept group than in the group treated with standard therapy alone. This study was undertaken to further explore the potential association between anti‐TNF therapy and the development of malignancy in these patients.Methods: One hundred eighty patients with active WG were enrolled and followed up for a median of 27 months. At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded. During the trial, the occurrence of malignancies and other adverse events was recorded prospectively.Results: All 6 solid malignancies observed during the WGET occurred in the etanercept group (P = 0.01 versus placebo group); based on a comparison of age‐ and sex‐specific incidence rates, 1.92 solid malignancies would have been expected in this group. The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 each of metastatic cholangiocarcinoma, renal cell carcinoma, and breast carcinoma, and 1 recurrent liposarcoma. There were no differences between the 2 treatment groups in sex distribution, disease severity, personal or family history of cancer, or tobacco and alcohol use. The etanercept group was older at baseline and less likely to be newly diagnosed with WG at the time of randomization. Patients who developed solid tumors were older than patients who did not. All etanercept‐treated patients who developed solid tumors were also treated with cyclophosphamide during the trial. However, there were no differences between the groups in the amount of cyclophosphamide received during the trial or the percentage who had received cyclophosphamide before enrollment. There were also no differences in the mean duration of daily cyclophosphamide therapy or the maximum daily cyclophosphamide dosage before enrollment.Conclusion: Data from the WGET, the first substantial reported experience of the combined use of etanercept and cyclophosphamide in the treatment of WG, indicate that the combination of TNF inhibition and cyclophosphamide may heighten the risk of cancer beyond that observed with cyclophosphamide alone.
- 27 April 2006
- Published by Wiley in Arthritis & Rheumatism
- Vol. 54 (5) , 1608-1618
Solid malignancies among patients in the Wegener's granulomatosis etanercept trial
Objective: Etanercept is a soluble fusion protein designed to inhibit tumor necrosis factor (TNF). During the Wegener's Granulomatosis Etanercept Trial (WGET), a placebo‐controlled trial of etanercept given in addition to standard therapy for remission induction and maintenance, more solid malignancies were observed in the etanercept group than in the group treated with standard therapy alone. This study was undertaken to further explore the potential association between anti‐TNF therapy and the development of malignancy in these patients.Methods: One hundred eighty patients with active WG were enrolled and followed up for a median of 27 months. At enrollment, disease characteristics, treatment history, specific medical history items, and information about previous WG treatments and risk factors for malignancy were recorded. During the trial, the occurrence of malignancies and other adverse events was recorded prospectively.Results: All 6 solid malignancies observed during the WGET occurred in the etanercept group (P = 0.01 versus placebo group); based on a comparison of age‐ and sex‐specific incidence rates, 1.92 solid malignancies would have been expected in this group. The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 each of metastatic cholangiocarcinoma, renal cell carcinoma, and breast carcinoma, and 1 recurrent liposarcoma. There were no differences between the 2 treatment groups in sex distribution, disease severity, personal or family history of cancer, or tobacco and alcohol use. The etanercept group was older at baseline and less likely to be newly diagnosed with WG at the time of randomization. Patients who developed solid tumors were older than patients who did not. All etanercept‐treated patients who developed solid tumors were also treated with cyclophosphamide during the trial. However, there were no differences between the groups in the amount of cyclophosphamide received during the trial or the percentage who had received cyclophosphamide before enrollment. There were also no differences in the mean duration of daily cyclophosphamide therapy or the maximum daily cyclophosphamide dosage before enrollment.Conclusion: Data from the WGET, the first substantial reported experience of the combined use of etanercept and cyclophosphamide in the treatment of WG, indicate that the combination of TNF inhibition and cyclophosphamide may heighten the risk of cancer beyond that observed with cyclophosphamide alone.
- 15 February 2006
- Published by Wiley in Arthritis & Rheumatism
- Vol. 55 (1) , 167-170
Churg-strauss syndrome presenting with salivary gland enlargement and respiratory distress
- 15 February 2006
- Published by Wiley in Arthritis & Rheumatism
- Vol. 55 (1) , 167-170
Churg-strauss syndrome presenting with salivary gland enlargement and respiratory distress
- 1 January 2006
- Vol. 69 (2) , 31-2
Hearing voices.
- 15 August 2005
- Published by Wiley in Arthritis & Rheumatism
- Vol. 53 (4) , 484-487
New journal policy regarding registration of clinical trials
- 15 August 2005
- Published by Wiley in Arthritis & Rheumatism
- Vol. 53 (4) , 484-487
New journal policy regarding registration of clinical trials
- Open Access
- 28 July 2005
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (8) , 2243-2247
New journal policy regarding registration of clinical trials
- 28 July 2005
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (8) , 2243-2247
Open AccessNew journal policy regarding registration of clinical trials
- Open Access
- 28 June 2005
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (7) , 2168-2178
Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)
Objective: To analyze damage occurring in patients with Wegener's granulomatosis (WG) enrolled in the WG Etanercept Trial (WGET) and to correlate that damage with disease activity, adverse events, and quality of life.Methods: The Vasculitis Damage Index (VDI) was applied to all 180 patients at trial entry and every 6 months throughout the trial. Items of damage were analyzed by presumed etiology (i.e., secondary to WG, to therapy, or both) and time of occurrence. Spearman's rank correlation coefficients were calculated between VDI scores and the Birmingham Vasculitis Activity Score for WG (BVAS/WG), frequency of flares, number of adverse events, and the patients' quality‐of‐life assessments.Results: The mean VDI score was 1.3 at the study enrollment and 1.8 at the end of the trial. This increase was due to damage that occurred despite (or because of) therapy, including visual impairment, hearing loss, nasal blockade, pulmonary fibrosis, hypertension, renal insufficiency, peripheral neuropathy, gonadal failure, and diabetes mellitus. Only 11% of the enrolled patients had not sustained a single VDI item after 1 year of enrollment. When adjusted for baseline VDI, the baseline BVAS/WG correlated moderately well with the VDI score at 1 year (r = 0.20, P = 0.015). Increases in adjusted VDI scores also correlated with the number of adverse events, particularly among patients with limited WG (P = 0.06).Conclusion: Damage from both active disease and its treatment remain important problems for patients with WG. Despite the dramatic improvements in patient survival achieved over the last several decades, only a few patients with WG emerge from a period of active disease without sustaining some damage from the disease itself, its treatment, or both. An important measure of future therapeutic approaches will be their ability to reduce the damage accrued over time.
- 28 June 2005
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (7) , 2168-2178
Open AccessDamage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)
Objective: To analyze damage occurring in patients with Wegener's granulomatosis (WG) enrolled in the WG Etanercept Trial (WGET) and to correlate that damage with disease activity, adverse events, and quality of life.Methods: The Vasculitis Damage Index (VDI) was applied to all 180 patients at trial entry and every 6 months throughout the trial. Items of damage were analyzed by presumed etiology (i.e., secondary to WG, to therapy, or both) and time of occurrence. Spearman's rank correlation coefficients were calculated between VDI scores and the Birmingham Vasculitis Activity Score for WG (BVAS/WG), frequency of flares, number of adverse events, and the patients' quality‐of‐life assessments.Results: The mean VDI score was 1.3 at the study enrollment and 1.8 at the end of the trial. This increase was due to damage that occurred despite (or because of) therapy, including visual impairment, hearing loss, nasal blockade, pulmonary fibrosis, hypertension, renal insufficiency, peripheral neuropathy, gonadal failure, and diabetes mellitus. Only 11% of the enrolled patients had not sustained a single VDI item after 1 year of enrollment. When adjusted for baseline VDI, the baseline BVAS/WG correlated moderately well with the VDI score at 1 year (r = 0.20, P = 0.015). Increases in adjusted VDI scores also correlated with the number of adverse events, particularly among patients with limited WG (P = 0.06).Conclusion: Damage from both active disease and its treatment remain important problems for patients with WG. Despite the dramatic improvements in patient survival achieved over the last several decades, only a few patients with WG emerge from a period of active disease without sustaining some damage from the disease itself, its treatment, or both. An important measure of future therapeutic approaches will be their ability to reduce the damage accrued over time.
- Open Access
- 4 March 2005
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (3) , 902-910
A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis
- 4 March 2005
- Published by Wiley in Arthritis & Rheumatism
- Vol. 52 (3) , 902-910
Open AccessA serum proteomic approach to gauging the state of remission in Wegener's granulomatosis
- 10 November 2004
- Published by American Medical Association (AMA) in JAMA
- Vol. 292 (18) , 2263-2270
Human Monocytic Ehrlichiosis
Review from JAMA — Human Monocytic Ehrlichiosis — A 56-year-old man with a history of Wegener granulomatosis presented with 6 days of sinus congestion, fever, malaise, myalgias, episcleritis, and a morbilliform rash. An exacerbation of Wegener granulomatosis was the principal concern because of the frequency of flares in that disease. The patient developed acute renal failure, thrombocytopenia, transaminitis, and, finally, severe myocarditis that led to congestive heart failure. Additional history-taking and the evolution of his clinical features led to empirical treatment with doxycycline for human monocytic ehrlichiosis (HME). The diagnosis of HME was confirmed by both a polymerase chain reaction assay for Ehrlichia chaffeensis and by the demonstration of morulae within peripheral blood mononuclear cells. The patient improved promptly following institution of doxycycline, and his cardiac function returned to normal over a period of 4 months.
- 10 November 2004
- Published by American Medical Association (AMA) in JAMA
- Vol. 292 (18) , 2263-2270
Human Monocytic Ehrlichiosis
Review from JAMA — Human Monocytic Ehrlichiosis — A 56-year-old man with a history of Wegener granulomatosis presented with 6 days of sinus congestion, fever, malaise, myalgias, episcleritis, and a morbilliform rash. An exacerbation of Wegener granulomatosis was the principal concern because of the frequency of flares in that disease. The patient developed acute renal failure, thrombocytopenia, transaminitis, and, finally, severe myocarditis that led to congestive heart failure. Additional history-taking and the evolution of his clinical features led to empirical treatment with doxycycline for human monocytic ehrlichiosis (HME). The diagnosis of HME was confirmed by both a polymerase chain reaction assay for Ehrlichia chaffeensis and by the demonstration of morulae within peripheral blood mononuclear cells. The patient improved promptly following institution of doxycycline, and his cardiac function returned to normal over a period of 4 months.
- 5 October 2004
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 141 (7) , 568-569
Methotrexate in Polymyalgia Rheumatica: Kernel of Truth or Curse of Tantalus?
- 5 October 2004
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 141 (7) , 568-569
Methotrexate in Polymyalgia Rheumatica: Kernel of Truth or Curse of Tantalus?
- 3 August 2004
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 141 (3) , 241-242
Of Ears and E-mails
- 3 August 2004
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 141 (3) , 241-242
Of Ears and E-mails